Anti-candida albicans combined medicament

A Candida albicans and drug technology, applied in antifungal agents, pharmaceutical formulations, organic active ingredients, etc., can solve the problems such as research reports on the anti-CA effect and mechanism research of the combination of DHA and FLC that have not been retrieved, and achieve reversal of drug resistance. the effect of enhancing antibacterial activity

Active Publication Date: 2020-07-17
SHANDONG RES INST OF TUMOUR PREVENTION TREATMENT
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After retrieving domestic and foreign literatures, there is no r

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-candida albicans combined medicament
  • Anti-candida albicans combined medicament
  • Anti-candida albicans combined medicament

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0021] Example 1: Determination of static effect of dihydroartemisinin combined with fluconazole against Candida albicans

[0022] 1. Materials

[0023] 1.1 Experimental strains

[0024] Quality control standard strain: Candida parapsilosis (CP) standard strain CP (obtained from American Type Culture Collection with deposit number ATCC22019).

[0025] Experimental strains: Candida albicans isolated from the clinic. The Candida albicans used in the experiment were all samples submitted by clinical patients in the Laboratory Department of Shandong Cancer Hospital. They were identified and confirmed by CHROMagar color identification medium. Preservation, the obtained Candida albicans strains were numbered as CA1, CA2, CA5, CA6 and CA7, and according to the drug susceptibility test results, CA5, CA6 and CA7 were Candida albicans resistant to fluconazole, while CA1 and CA1 were CA2 is a fluconazole-sensitive Candida albicans.

[0026] 1.2 Drugs and Reagents

[0027] Fluconazole...

Example Embodiment

[0064] Example 2: Determination of the dynamic effect of dihydroartemisinin and fluconazole in combination against Candida albicans

[0065] 1. Materials

[0066] 1.1 Strains

[0067] The strains used in the experiment were clinically isolated Candida albicans CA5 and CA6 that were resistant to fluconazole, which were identified and confirmed by Chromachya yeast identification medium, and subcultured on solid medium.

[0068] 1.2 Drugs and Reagents

[0069] APIs of DHA and FLC; DMSO; PBS buffer; 0.1mol / L NaOH solution; RPMI1640; XTT-menaquinone solution; Example 1 is the same.

[0070] 1.3 Instruments

[0071] Constant temperature incubator, high temperature and autoclave sterilizer, ultra-clean workbench (all the same as the above-mentioned Example 1); constant temperature oscillator (Germany IKA company).

[0072] 2. Content and method

[0073] In this experiment, a single drug and drug combination action system was established, which was shaken and cultured at 35 °C f...

Example Embodiment

[0086] Example 3: Study on the mechanism of action of dihydroartemisinin combined with fluconazole against Candida albicans

[0087] 1. Materials

[0088] 1.1 Experimental strains

[0089] The clinically isolated Candida albicans CA5 was thawed from a -20°C refrigerator, and then subcultured on YPD solid medium for at least 3 times before use.

[0090] 1.2 Drugs and Reagents

[0091] The raw materials of DHA and FLC, the preparation method is the same as the above-mentioned embodiment 1;

[0092] 2',7'-dichlorofluorescein yellow diacetate (DCFH-DA) mother liquor: Weigh 0.040g DCFH-DA (Shandong Zengfeng Biotechnology Co., Ltd.) and dissolve it in 5mL DMSO to make a concentration of 8mg / mL. 0.22μm microporous membrane (same as the above-mentioned Example 1) was filtered and sterilized, and stored at -20°C in the dark;

[0093] YPD liquid medium: Weigh 4g yeast extract, 8g peptone and 8g glucose respectively, add appropriate amount of distilled water and stir to dissolve grad...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Concentrationaaaaaaaaaa
Login to view more

Abstract

The invention discloses an anti-candida albicans combined medicament, and belongs to the field of antifungal medicaments. The anti-candida albicans combined medicament comprises dihydroartemisinin andfluconazole. According to the research of the prior art, the dihydroartemisinin is used as a non-antifungal drug, and the dihydroartemisinin has almost no antifungal effect when being used alone. However, according to the research in the invention, antibacterial activity of fluconazole to drug-resistant candida albicans can be enhanced through combined application of the dihydroartemisinin and the fluconazole, and a synergistic antifungal effect is generated. In addition, drug resistance of candida albicans to the fluconazole is reversed by inducing generation of intracellular active oxygen,and the invention provide a direction for development of novel antifungal drugs and for novel use of traditional Chinese medicines.

Description

technical field [0001] The invention belongs to the field of antifungal drugs, in particular to an anti-candida albicans combination drug, and more specifically to the antifungal effect of dihydroartemisinin and fluconazole combined. Background technique [0002] In recent years, with the increasing number of cancer patients and patients with autoimmune diseases, and the widespread application of hormones, the incidence of fungal infections has increased year by year. Among fungal infections, infections caused by Candida are more common. Candida is an opportunistic pathogenic bacteria, and Candida albicans (CA) is the Candida genus with the highest clinical isolation rate, and its drug resistance is increasing continuously. The mortality rate of deep tissue infection caused by CA is high. Treatment presents challenges. The communiqué of the G20 Hangzhou Summit has mentioned that antimicrobial resistance is a serious threat to public health, economic growth and global econo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4196A61K31/357A61P31/10
CPCA61K31/357A61K31/4196A61P31/10A61K2300/00
Inventor 李辉张慧丽陈海生王艳红刘玉国李慧
Owner SHANDONG RES INST OF TUMOUR PREVENTION TREATMENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap